Racura Oncology

03/09/2026

Racura Oncology CEO Dr. Daniel Tillett took the stage at the recent TechKnow Invest Roadshow, to share our approach to drug development and outline the potential of RC220.

Racura Oncology is rapidly advancing three clinical programs focused on MYC, a historically "undruggable” oncology target dysregulated in up to 70% of cancers.

The TechKnow presentation is now available to view - find the link here: https://announcements.racuraoncology.com/activity-updates/yOZDdP-racura-oncology-at-techknow-invest-roadshow-july-2026

Watch Racura Oncology's CEO, Dr Daniel Tillett present at TechKnow Invest Road Day 2 July 2026.

02/09/2026

The MYC protein has long been considered the 'holy grail' of oncology targets, yet remains notoriously difficult to silence. In this Racura Symposium highlight, VP of Research Prof Mike Kelso outlines our novel therapeutic approach to targeting MYC-driven cancers by binding to and stabilising three-dimensional DNA structures known as G-quadruplexes.

🎥 Learn more in the video

01/09/2026

Racura Oncology (ASX: RAC) is pleased to announce an important milestone for our CPACS Phase 1 trial, with Ewha Womans University Seoul Hospital becoming the first Korean site to open for patient enrolment.

The CPACS trial is evaluating RC220 in combination with doxorubicin in patients with advanced solid tumours, with the aim of investigating both cardioprotection and potential anticancer synergy.

Additional Korean sites, including Severance Hospital and Samsung Medical Center, are scheduled to be activated and opened for patient enrolment in the coming weeks.

The activation of these sites marks an important step forward for the CPACS trial, and is expected to accelerate patient recruitment and trial progress.

We thank our investigators and clinical teams in Korea as we advance RC220 through clinical development.

Read the full announcement here:https://announcements.racuraoncology.com/announcements/7710953

31/08/2026

Kicking off our series of key highlights from the Investor Symposium, which took place in March this year, CEO and Managing Director Dr Daniel Tillett details how Racura Oncology stands as a unique, clinically de-risked biotech investment on the ASX.

Considering the traditional 0.1 per cent success rate of advancing a drug to approval, our lead asset (E,E)-bisantrene is distinct, having secured prior approval for AML in France under a preceding formulation bolstered by a demonstrated efficacy over a 40-year period.

🎥 Watch the overview

21/08/2026

An article from Racura Oncology CEO Dr Daniel Tillett has been published in Drug Target Review sharing his thoughts on why Racura is reviving bisantrene, a cancer therapy developed decades ago and abandoned, and the scientific insights from Racura’s researchers driving the renewed interest.

These insights have driven the development of RC220, our novel formulation of bisantrene, and have advanced its use across multiple cancer indications.

As Daniel explains: “What began as a programme aimed at reviving bisantrene for a niche application has expanded into a deeper understanding of the molecule’s mechanism of action and its potential role in targeting MYC.”

Read the full article here: https://www.drugtargetreview.com/home/why-researchers-are-revisiting-bisantrene-decades-after-it-was-abandoned/2136265.article

19/08/2026

This Daffodil Day (Cancer Council Australia) marks 40 years of growing hope for everyone affected by cancer, a vital reminder of why advancing cancer research remains critical.

At Racura Oncology, our target is clear: delivering better and safer outcomes for patients with cancer. Through our novel lead asset, RC220, we are advancing multiple clinical trials aiming to improve the outcomes of patients while helping them avoid the serious side effects that come with conventional cancer treatments.

Find the link with more information about Daffodil Day in the comments.

13/08/2026

Racura Oncology CEO Dr Daniel Tillett was interviewed by Andrew Wilkinson, Senior Investment Analyst at Venn Brown, to discuss our clinical and corporate strategy in depth.

They covered our three development pathways and ongoing trials, and dived into how we have reformulated bisantrene to target the MYC protein, oncology’s largest untapped opportunity. The research also covers the relative risk, commercial potential, and timing of each program.

Read the full research piece here: https://www.vennbrown.com/research-report/racura-oncology-one-drug-three-shots

07/08/2026

Racura Oncology Executive Chair Dr Pete Smith delivered a presentation this morning, on day two of the 20th edition of the Bioshares Biotech Summit. Pete gave an overview of Racura’s innovative approach to targeting the MYC protein, the ‘holy grail’ of cancer targets; our ongoing clinical trials across multiple indications; and the significant market opportunity.

The presentation followed a panel chaired by Pete yesterday on ‘Healthspan and Longevity’ - one of the most important, and most-discussed topics in Biotech development today, which featured insights and commentary from leaders in the space, including Cogstate, Acrux, Lateral Pharma, and Artrya.

Thank you to Bioshares, and to Pachacz for hosting the event.

07/08/2026

Racura Oncology (ASX: RAC) is looking forward to presenting at the Twilight Investor Briefing, hosted by FB Rice and Monsoon Communications on Tuesday, 11 August at 3.45 PM at the FB Rice offices, Sydney.

The event will showcase three ASX listed biotech companies at the forefront of cancer research, including Racura.

CEO Dr Daniel Tillett will be discussing how our lead asset (E,E) bisantrene, has been discovered to silence MYC, long considered the ‘Holy Grail’ of cancer targets, as well as our three ongoing clinical trials across multiple indications.

For more information and to register, click here: https://docs.google.com/forms/d/e/1FAIpQLSdZPE5gqMi5Gl1rvfJm2Y0ag_crGy60Pb4_YcSdkyAgggNouw/viewform

14/07/2026

Racura Oncology was pleased to present at the JP Equity Partners ‘Boom of the Biotech II’ Investor Briefing last month, with CEO Dr Daniel Tillett providing an overview of Racura’s recent corporate and clinical highlights.

The evening featured innovation, ideas and insights from investors and presenting companies. Thank you for having us, JP Equity partners and Samphire Rottnest.